Skip to main content

Table 1 Clinical features of lung adenocarcinoma cases. Patient clinical information and tumor characteristics for recurrent and non-recurrent lung adenocarcinoma cases (n = 20)

From: Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence

Patient ID Recurrence Recurrence site Predominant Histological Pattern Age Sex T N M Max. Dimension (cm) Stage Adjuvant chemo-therapya Adjuvant radiation Smoking Mutation Survival (Months)
P1 NA   Acinar 71 F 1 0 0 2.8 IA No No CS KRAS 96
P2 No   Acinar 82 F 2 0 0 3 IB No No EX EGFR 81
P3   Acinar 68 F 1 0 0 1.8 IA No No NS WT 77
P4   Acinar 57 F 2 1 0 2.8 IIB Yes No CS KRAS 86
P5   Acinar 67 F 2 1 0 3.2 IIB Yes No CS WT 88
P6   Acinar 71 F 2 0 0 3.1 IB No No NS WT 26
P7   Acinar 70 M 1 0 0 2.3 IA No No CS NA 95
P8   Mucinous 86 F 2 0 0 3.2 IB No No NS KRAS 92
P9   Acinar 82 F 3 0 0 2.7 IIB No No NS EGFR 98
P10 Yes distant Acinar 73 F 4 1 0 2.8b IIA No No CS NA 63
P11 distant Acinar 77 F 2 0 0 3.4 IB No No NS WT 13
P12 distant Papillary 90 F 2 1 0 4.5 IIB No No EX WT 30
P13 local Mucinous 77 F 1 0 0 2.5 IA No No NS KRAS 76
P14 distant Acinar 53 F 2 2 0 7 IIIA No No CS KRAS 3
P15 local and distant Papillary 60 F 2 1 0 2.5 IIB Yes No EX EGFR 77
P16 local and distant Acinar 72 F 2 0 0 4.5 IB No No CS WT 61
P17 distant Acinar 58 M 2 1 0 2.5 IIB No No EX WT 30
P18 distant Micro-papillary 66 M 2 2 0 3.5 IIIA Yes No NS EGFR 58
P19 distant Papillary 77 F 2 1 0 4 IIB No No NS EGFR 46
P20 distant Acinar 78 F 1 0 0 1.2 IA No No CS KRAS 37
  1. M Male, F Female, CS Current Smoker, EX Former Smoker, NS Never Smoker
  2. aAdjuvant chemotherapy: cisplatin-vinorelbine, 4 cycles except for patient P4 who received 3 cycles of cyclophosphamide, doxorubicin and was then on tamoxifen because of synchronous breast cancer
  3. bplus four additional carcinomas removed, giving the final T4 classification